Methods for optimizing domain stability of binding proteins

Patent metadata

Field	Value
Publication number	US-9612247-B2
Application number	US-201414161552-A
Country	US
Kind code	B2
Filing date	Jan 22, 2014
Priority date	Jan 22, 2013
Publication date	Apr 4, 2017
Grant date	Apr 4, 2017

Abstract

Provided are methods for measuring the inherent stability of intrachain disulphide-containing domains (e.g., antibody variable domains) and for optimizing the positioning of intrachain disulphide-containing domains within a protein (e.g., a multispecific binding protein, e.g., a DVD-Ig). Also provided are methods of making multispecific binding proteins (e.g., DVD-Ig molecules) comprising two or more antibody variable domains in which the antibody variable domains are optimally positioned within the multispecific binding proteins to enhance stability of the multispecific binding protein. Multispecific binding proteins optimized using the methods disclosed herein are also provided.

First claim

We claim:

1. A method of determining the optimal relative positioning of an inner antibody variable domain and an outer antibody variable domain in a multispecific binding protein, the method comprising:
a) providing a first antibody variable domain and a second antibody variable domain;
b) contacting the first antibody variable domain and the second antibody variable domain with a first predetermined concentration of a denaturing agent selected from the group consisting of a chaotropic agent and a detergent, wherein the denaturing agent does not cause complete denaturation of the first antibody variable domain and the second antibody variable domain;
c) contacting the first antibody variable domain and the second antibody variable domain with a first detectable sulfhydryl-reactive alkylating reagent under reducing conditions such that all reducible sulfhydryl groups in the first antibody variable domain and the second antibody variable domain are alkylated;
d) contacting the first antibody variable domain and the second antibody variable domain with a second predetermined concentration of the denaturing agent that is greater than the first predetermined concentration and causes complete denaturation of the first antibody variable domain and the second antibody variable domain;
e) contacting the first antibody variable domain and the second antibody variable domain with a second detectable sulfhydryl-reactive alkylating reagent that is distinguishable from the first detectable sulfhydryl-reactive alkylating reagent under reducing conditions such that all reducible sulfhydryl groups in the first antibody variable domain and the second antibody variable domain are alkylated;
f) measuring the relative amount of the first and second detectable sulfhydryl-reactive alkylating reagents incorporated into the first antibody variable domain and the second antibody variable domain relative to a suitable control,
wherein the relative amount of incorporation of the first sulfhydryl-reactive alkylating reagent inversely correlates with the stability of the first antibody variable domain and the second antibody variable domain;
g) determining whether the first antibody variable domain is more or less stable than the second antibody variable domain, thereby identifying a less stable antibody variable domain and a more stable antibody variable domain; and
h) identifying the less stable antibody variable domain as being suitable as an inner variable domain in a multispecific binding protein and the more stable antibody variable domain as being suitable as an outer variable domain in the multispecific binding protein, thereby determining the optimal relative positioning of the first and the second antibody variable domain in the multispecific binding protein wherein the chaotropic agent is selected from the group consisting of guanidine hydrochloride, guanidine thiocyanate, urea, thiourea, sodium trichloroacetate, trifluoroethanol (TFE), butanol, ethanol, lithium perchlorate, lithium acetate, magnesium chloride, phenol, and propanol and wherein the detergent is selected from the group consisting of Octyl-b-Dglucopyranoside, Decyl-b-D-1-thioglucopyranoside, Octyl-b-Dthioglucopyranoside, Digitonin, Dimethyldecylphosphine, oxide (APO-10), Dodecyldimethylphosphine, oxide (APO-12), octylphenoxypolyethoxyethanol, N-octyl glucoside, N-Octanoyl-N-methylglucamine (MEGA-8), N-Nonanoyl-N-methylglucamine (MEGA-9), N-Decanoyl-N-methylglucamine (MEGA-10), 4-Nonylphenyl-polyethylene glycol, Polyoxyethylene-polyoxypropylene block copolymer, Saponin, Polyethylene glycol tert-octylphenyl ether, polysorbate 20, polysorbate 40, polysorbate 80, Sodium cholate, Sodium deoxycholate, Sodium glycocholate, Sodium taurocholate, Sodium taurodeoxycholate, N-Lauroylsarcosine, Lithium dodecyl sulfate, Sodium dodecyl sulfate (SDS), Hexadecyltrimethyl ammonium bromide (CTAB), Trimethyl(tetradecyl)ammonium bromide (TTAB), ASB-14 (amidosulfobetaine-14), ASB-16 (amidosulfobetaine-16), C7BzO, CHAPS, CHAPSO, N,N-Dimethyl-N-dodecylglycine betaine, 3-(N,N-Dimethyloctylammonio)propanesulfonate inner salt (SB3-8), 3-(Decyldimethylammonio)propanesulfonate inner salt (SB3-10), 3-(Dodecyldimethylammonio)propanesulfonate inner salt (SB3-12), 3-(N,N-Dimethylmyristylammonio)propanesulfonate (SB3-14), 3-(N,N-Dimethylpalmitylammonio)propanesulfonate (SB3-16), 3-(N,N-Dimethyloctadecylammonio)propanesulfonate (SB3-18), 3-(1-Pyridinio)-1-propanesulfonate (NDSB 201), and 3-(Benzyldimethylammonio)propanesulfonate (NDSB 256).

2. The method of claim 1 , wherein the first antibody variable domain and the second antibody variable domain are contained within a multispecific binding protein, wherein one of the first and second antibody variable domains is an inner antibody variable domain and the other of the first and second antibody variable domains is an outer antibody variable domain.

3. The method of claim 2 , wherein the multispecific binding protein is a DVD-Ig, or antigen binding fragment thereof, comprising the inner antibody variable domain and the outer antibody variable domain.

4. The method of claim 1 , wherein the suitable control is a VH, a VL, a CH1, a CH2, a CH3 and/or a CL domain.

5. The method of claim 1 , wherein the suitable control is a reference value of alkylating reagent incorporation.

6. The method of claim 1 , wherein the amount of first detectable sulfhydryl-reactive alkylating reagent incorporated into the first antibody variable domain and the second antibody variable domain is measured at more than one predetermined concentration of a denaturing agent.

7. The method of claim 1 , wherein the amount of first and second detectable sulfhydryl-reactive alkylating reagent incorporated into the first antibody variable domain and the second antibody variable domain is measured by mass spectrometry of alkylated peptides from the first antibody variable domain and the second antibody variable domain.

8. The method of claim 1 , wherein the second detectable sulfhydryl-reactive alkylating reagent is an isotope variant of the first detectable sulfhydryl-reactive alkylating reagent.

9. The method of claim 1 , wherein the first and/or second detectable sulfhydryl-reactive alkylating reagent is selected from the group consisting of iodoacetic acid (IAA), iodoacetamide (IAM), bromoacetic acid, bromoacetamide, N-ethylmaleimide (NEM), N-methyliodomaleimide, N-methylbromomaleimide, N-phenyliodomaleimide, N-phenylbromomaleimide, N-tert-butyl-2-iodoacetamide (N-t-butyliodoacetamide), 2-iodo-N-phenylacetamide (iodoacetanilide), acrylamide, vinylsulfamide, N-isopropyliodoacetamide (NIPIA), and/or N-isopropylbromoacetamide (NIPBRA).

10. The method of claim 1 , wherein the second detectable sulfhydryl-reactive alkylating reagent is a heavy isotope variant of the first alkylating reagent.

11. The method of claim 1 , wherein the second detectable sulfhydryl-reactive alkylating reagent is a lighter isotope variant of the first alkylating reagent.

12. The method of claim 1 , wherein the first detectable sulfhydryl-reactive alkylating reagent is 12 C-iodoacetic acid.

13. The method of claim 1 , wherein the first detectable sulfhydryl-reactive alkylating reagent is C-iodoacetic acid.

14. The method of claim 1 , wherein the second detectable sulfhydryl-reactive alkylating reagent is 12 C-iodoacetic acid.

15. The method of claim 1 , wherein the second detectable sulfhydryl-reactive alkylating reagent is 13 C-iodoacetic acid.

16. The method of claim 1 , wherein the concentration of the first and/or second detectable sulfhydryl-reactive alkylating reagent is 25 nM.

17

Assignees

• Abbvie Inc
• Abbvie Inc

Inventors

• Chumsae Chris M
• Radziejewskia Czeslaw H
• Manuilov Anton

Classifications

• G01N33/6854 Primary

  Immunoglobulins · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K16/244

  Interleukins [IL] · CPC title

• C07K16/22

  against growth factors {; against growth regulators} · CPC title

• C07K16/4291

  against IgE · CPC title